Fumarylacetoacetate hydrolase deficient pigs are a novel large animal model of metabolic liver disease

Stem Cell Research

Volumn 13, Issue 1, 2014, Pages 144-153

  Hickey, Raymond D ^a   Mao, Shennen A ^a   Glorioso, Jaime ^a   Lillegard, Joseph B ^b   Fisher, James E ^a   Amiot, Bruce ^a   Rinaldo, Piero ^a   Harding, Cary O ^c   Marler, Ronald ^d   Finegold, Milton J ^e   Grompe, Markus ^c   Nyberg, Scott L ^a  

^a MAYO CLINIC   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d MAYO CLINIC   (United States)

^e BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FUMARYLACETOACETASE; NITISINONE; HYDROLASE;

ACUTE LIVER FAILURE; ADENO ASSOCIATED VIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL NUCLEUS TRANSPLANTATION; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME DEFICIENCY; FEMALE; FIBROBLAST; GENE INACTIVATION; GENOTYPE; HEPATIC ENCEPHALOPATHY; HISTOLOGY; LIVER CELL DAMAGE; LIVER DISEASE; MALE; METABOLIC DISORDER; NONHUMAN; PHENOTYPE; PHYSICAL EXAMINATION; PREGNANCY; PRIORITY JOURNAL; SOMATIC CELL; TYROSINEMIA; ANIMAL; DEFICIENCY; DISEASE MODEL; ENZYMOLOGY; METABOLISM; PIG;

ANIMALS; DISEASE MODELS, ANIMAL; FEMALE; GENE KNOCKOUT TECHNIQUES; GENOTYPE; HYDROLASES; LIVER DISEASES; MALE; PREGNANCY; SWINE; TYROSINEMIAS;

EID: 84901477570     PISSN: 18735061     EISSN: 18767753     Source Type: Journal    
DOI: 10.1016/j.scr.2014.05.003     Document Type: Article

References (53)

1. -/- mice. Nat. Biotechnol. 2007, 25:903-910.
2. Christianson W.T. Stillbirths, mummies, abortions, and early embryonic death. Vet. Clin. North Am. Food Anim. Pract. 1992, 8:623-639.
3. Cooper D.K., Gollackner B., Sachs D.H. Will the pig solve the transplantation backlog?. Annu. Rev. Med. 2002, 53:133-147.
4. de Laet C., Dionisi-Vici C., Leonard J.V., McKiernan P., Mitchell G., Monti L., de Baulny H.O., Pintos-Morell G., Spiekerkotter U. Recommendations for the management of tyrosinaemia type 1. Orphanet J. Rare Dis. 2013, 8:8.
5. De Vree J.M., Ottenhoff R., Bosma P.J., Smith A.J., Aten J., Oude Elferink R.P. Correction of liver disease by hepatocyte transplantation in a mouse model of progressive familial intrahepatic cholestasis. Gastroenterology 2000, 119:1720-1730.
6. Endo F., Sun M.S. Tyrosinaemia type I and apoptosis of hepatocytes and renal tubular cells. J. Inherit. Metab. Dis. 2002, 25:227-234.
7. Espejel S., Roll G.R., McLaughlin K.J., Lee A.Y., Zhang J.Y., Laird D.J., Okita K., Yamanaka S., Willenbring H. Induced pluripotent stem cell-derived hepatocytes have the functional and proliferative capabilities needed for liver regeneration in mice. J. Clin. Invest. 2010, 120:3120-3126.
8. Fisher R.A., Strom S.C. Human hepatocyte transplantation: worldwide results. Transplantation 2006, 82:441-449.
9. Fisher J.E., Lillegard J.B., McKenzie T.J., Rodysill B.R., Wettstein P.J., Nyberg S.L. In utero transplanted human hepatocytes allow postnatal engraftment of human hepatocytes in pigs. Liver Transplant. 2013, 19:328-335.
10. Fox I.J., Chowdhury J.R., Kaufman S.S., Goertzen T.C., Chowdhury N.R., Warkentin P.I., Dorko K., Sauter B.V., Strom S.C. Treatment of the Crigler-Najjar syndrome type I with hepatocyte transplantation. N. Engl. J. Med. 1998, 338:1422-1426.
11. Gagne R., Lescault A., Grenier A., Laberge C., Melancon S.B., Dallaire L. Prenatal diagnosis of hereditary tyrosinaemia: measurement of succinylacetone in amniotic fluid. Prenat. Diagn. 1982, 2:185-188.
12. Garcia Segarra N., Roche S., Imbard A., Benoist J.F., Greneche M.O., Davit-Spraul A., Ogier de Baulny H. Maternal and fetal tyrosinemia type I. J. Inherit. Metab. Dis. 2010, 33(Suppl. 3):S507-S510.
13. Gluecksohn-Waelsch S. Genetic control of morphogenetic and biochemical differentiation: lethal albino deletions in the mouse. Cell 1979, 16:225-237.
14. Grompe M. The pathophysiology and treatment of hereditary tyrosinemia type 1. Semin. Liver Dis. 2001, 21:563-571.
15. Grompe M., al-Dhalimy M., Finegold M., Ou C.N., Burlingame T., Kennaway N.G., Soriano P. Loss of fumarylacetoacetate hydrolase is responsible for the neonatal hepatic dysfunction phenotype of lethal albino mice. Genes Dev. 1993, 7:2298-2307.
16. Hall M.G., Wilks M.F., Provan W.M., Eksborg S., Lumholtz B. Pharmacokinetics and pharmacodynamics of NTBC (2-(2-nitro-4-fluoromethylbenzoyl)-1,3-cyclohexanedione) and mesotrione, inhibitors of 4-hydroxyphenyl pyruvate dioxygenase (HPPD) following a single dose to healthy male volunteers. Br. J. Clin. Pharmacol. 2001, 52:169-177.
17. Hamman K., Clark H., Montini E., Al-Dhalimy M., Grompe M., Finegold M., Harding C.O. Low therapeutic threshold for hepatocyte replacement in murine phenylketonuria. Mol. Ther. 2005, 12:337-344.
18. Hansen K., Horslen S. Metabolic liver disease in children. Liver Transplant. 2008, 14:713-733.
19. Haridass D., Yuan Q., Becker P.D., Cantz T., Iken M., Rothe M., Narain N., Bock M., Norder M., Legrand N., Wedemeyer H., Weijer K., Spits H., Manns M.P., Cai J., Deng H., Di Santo J.P., Guzman C.A., Ott M. Repopulation efficiencies of adult hepatocytes, fetal liver progenitor cells, and embryonic stem cell-derived hepatic cells in albumin-promoter-enhancer urokinase-type plasminogen activator mice. Am. J. Pathol. 2009, 175:1483-1492.
20. Hickey R.D., Lillegard J.B., Fisher J.E., McKenzie T.J., Hofherr S.E., Finegold M.J., Nyberg S.L., Grompe M. Efficient production of Fah-null heterozygote pigs by chimeric adeno-associated virus-mediated gene knockout and somatic cell nuclear transfer. Hepatology 2011, 54:1351-1359.
21. Hostetter M.K., Levy H.L., Winter H.S., Knight G.J., Haddow J.E. Evidence for liver disease preceding amino acid abnormalities in hereditary tyrosinemia. N. Engl. J. Med. 1983, 308:1265-1267.
22. Huang P., He Z., Ji S., Sun H., Xiang D., Liu C., Hu Y., Wang X., Hui L. Induction of functional hepatocyte-like cells from mouse fibroblasts by defined factors. Nature 2011, 475:386-389.
23. Huch M., Dorrell C., Boj S.F., van Es J.H., Li V.S.W., van de Wetering M., Sato T., Hamer K., Sasaki N., Finegold M.J., Haft A., Vries R.G., Grompe M., Clevers H. In vitro expansion of single Lgr5(+) liver stem cells induced by Wnt-driven regeneration. Nature 2013, 494:247-250.
24. Jorquera R., Tanguay R.M. The mutagenicity of the tyrosine metabolite, fumarylacetoacetate, is enhanced by glutathione depletion. Biochem. Biophys. Res. Commun. 1997, 232:42-48.
25. Kubo S., Sun M., Miyahara M., Umeyama K., Urakami K., Yamamoto T., Jakobs C., Matsuda I., Endo F. Hepatocyte injury in tyrosinemia type 1 is induced by fumarylacetoacetate and is inhibited by caspase inhibitors. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:9552-9557.
26. Li T., Huang J., Jiang Y., Zeng Y., He F., Zhang M.Q., Han Z., Zhang X. Multi-stage analysis of gene expression and transcription regulation in C57/B6 mouse liver development. Genomics 2009, 93:235-242.
27. Lindblad B., Lindstedt S., Steen G. On the enzymic defects in hereditary tyrosinemia. Proc. Natl. Acad. Sci. U. S. A. 1977, 74:4641-4645.
28. Lindstedt S., Holme E., Lock E.A., Hjalmarson O., Strandvik B. Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase. Lancet 1992, 340:813-817.
29. Lisowski L., Lau A., Wang Z., Zhang Y., Zhang F., Grompe M., Kay M.A. Ribosomal DNA integrating rAAV-rDNA vectors allow for stable transgene expression. Mol. Ther. 2012, 20:1912-1923.
30. MacKenzie T.C., Kobinger G.P., Kootstra N.A., Radu A., Sena-Esteves M., Bouchard S., Wilson J.M., Verma I.M., Flake A.W. Efficient transduction of liver and muscle after in utero injection of lentiviral vectors with different pseudotypes. Mol. Ther. 2002, 6:349-358.
31. Matas A.J., Sutherland D.E., Steffes M.W., Mauer S.M., Sowe A., Simmons R.L., Najarian J.S. Hepatocellular transplantation for metabolic deficiencies: decrease of plasms bilirubin in Gunn rats. Science 1976, 192:892-894.
32. Matsunari H., Nagashima H., Watanabe M., Umeyama K., Nakano K., Nagaya M., Kobayashi T., Yamaguchi T., Sumazaki R., Herzenberg L.A., Nakauchi H. Blastocyst complementation generates exogenic pancreas in vivo in apancreatic cloned pigs. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:4557-4562.
33. Overturf K., Al-Dhalimy M., Tanguay R., Brantly M., Ou C.N., Finegold M., Grompe M. Hepatocytes corrected by gene therapy are selected in vivo in a murine model of hereditary tyrosinaemia type I. Nat. Genet. 1996, 12:266-273.
34. Paulk N.K., Wursthorn K., Wang Z., Finegold M.J., Kay M.A., Grompe M. Adeno-associated virus gene repair corrects a mouse model of hereditary tyrosinemia in vivo. Hepatology 2010, 51:1200-1208.
35. Prather R.S., Lorson M., Ross J.W., Whyte J.J., Walters E. Genetically engineered pig models for human diseases. Ann. Rev. Anim. Biosci. 2013, 1:203-219.
36. Renner S., Fehlings C., Herbach N., Hofmann A., von Waldthausen D.C., Kessler B., Ulrichs K., Chodnevskaja I., Moskalenko V., Amselgruber W., Goke B., Pfeifer A., Wanke R., Wolf E. Glucose intolerance and reduced proliferation of pancreatic beta-cells in transgenic pigs with impaired glucose-dependent insulinotropic polypeptide function. Diabetes 2010, 59:1228-1238.
37. Rogers C.S., Stoltz D.A., Meyerholz D.K., Ostedgaard L.S., Rokhlina T., Taft P.J., Rogan M.P., Pezzulo A.A., Karp P.H., Itani O.A., Kabel A.C., Wohlford-Lenane C.L., Davis G.J., Hanfland R.A., Smith T.L., Samuel M., Wax D., Murphy C.N., Rieke A., Whitworth K., Uc A., Starner T.D., Brogden K.A., Shilyansky J., McCray P.B., Zabner J., Prather R.S., Welsh M.J. Disruption of the CFTR gene produces a model of cystic fibrosis in newborn pigs. Science 2008, 321:1837-1841.
38. Ruppert S., Kelsey G., Schedl A., Schmid E., Thies E., Schutz G. Deficiency of an enzyme of tyrosine metabolism underlies altered gene expression in newborn liver of lethal albino mice. Genes Dev. 1992, 6:1430-1443.
39. Russell L.B., Russell W.L., Kelly E.M. Analysis of the albino-locus region of the mouse. I. Origin and viability. Genetics 1979, 91:127-139.
40. Russo P., O'Regan S. Visceral pathology of hereditary tyrosinemia type I. Am. J. Hum. Genet. 1990, 47:317-324.
41. Saeki K., Matsumoto K., Kinoshita M., Suzuki I., Tasaka Y., Kano K., Taguchi Y., Mikami K., Hirabayashi M., Kashiwazaki N., Hosoi Y., Murata N., Iritani A. Functional expression of a Delta12 fatty acid desaturase gene from spinach in transgenic pigs. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:6361-6366.
42. Schmelzer E., Zhang L., Bruce A., Wauthier E., Ludlow J., Yao H.L., Moss N., Melhem A., McClelland R., Turner W., Kulik M., Sherwood S., Tallheden T., Cheng N., Furth M.E., Reid L.M. Human hepatic stem cells from fetal and postnatal donors. J. Exp. Med. 2007, 204:1973-1987.
43. Si-Tayeb K., Noto F.K., Nagaoka M., Li J.X., Battle M.A., Duris C., North P.E., Dalton S., Duncan S.A. Highly efficient generation of human hepatocyte-like cells from induced pluripotent stem cells. Hepatology 2010, 51:297-305.
44. Sniderman King L., Trahms C., Scott C.R. Tyrosinemia type 1. Gene Reviews 1993, (Seattle (WA)). R.A. Pagon, M.P. Adam, T.D. Bird, C.R. Dolan, C.T. Fong, K. Stephens (Eds.).
45. Tanguay R.M., Valet J.P., Lescault A., Duband J.L., Laberge C., Lettre F., Plante M. Different molecular basis for fumarylacetoacetate hydrolase deficiency in the two clinical forms of hereditary tyrosinemia (type I). Am. J. Hum. Genet. 1990, 47:308-316.
46. Turgeon C., Magera M.J., Allard P., Tortorelli S., Gavrilov D., Oglesbee D., Raymond K., Rinaldo P., Matern D. Combined newborn screening for succinylacetone, amino acids, and acylcarnitines in dried blood spots. Clin. Chem. 2008, 54:657-664.
47. Vanclooster A., Devlieger R., Meersseman W., Spraul A., Kerckhove K.V., Vermeersch P., Meulemans A., Allegaert K., Cassiman D. Pregnancy during nitisinone treatment for tyrosinaemia type I: first human experience. JIMD Rep. 2012, 5:27-33.
48. Wang X., Montini E., Al-Dhalimy M., Lagasse E., Finegold M., Grompe M. Kinetics of liver repopulation after bone marrow transplantation. Am. J. Pathol. 2002, 161:565-574.
49. Wilson J.M., Johnston D.E., Jefferson D.M., Mulligan R.C. Correction of the genetic defect in hepatocytes from the Watanabe heritable hyperlipidemic rabbit. Proc. Natl. Acad. Sci. U. S. A. 1988, 85:4421-4425.
50. Yamada T., Yoshikawa M., Kanda S., Kato Y., Nakajima Y., Ishizaka S., Tsunoda Y. In vitro differentiation of embryonic stem cells into hepatocyte-like cells identified by cellular uptake of indocyanine green. Stem Cells 2002, 20:146-154.
51. Yoshida Y., Tokusashi Y., Lee G.H., Ogawa K. Intrahepatic transplantation of normal hepatocytes prevents Wilson's disease in Long-Evans cinnamon rats. Gastroenterology 1996, 111:1654-1660.
52. Yu Y., Liu H., Ikeda Y., Amiot B.P., Rinaldo P., Duncan S.A., Nyberg S.L. Hepatocyte-like cells differentiated from human induced pluripotent stem cells: relevance to cellular therapies. Stem Cell Res. 2012, 9:196-207.
53. Zhu S., Rezvani M., Harbell J., Mattis A.N., Wolfe A.R., Benet L.Z., Willenbring H., Ding S. Mouse liver repopulation with hepatocytes generated from human fibroblasts. Nature 2014, 508:93-97.